



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

# Impact of the COVID-19 pandemic on cardiometabolic health parameters in children with preexisting dyslipidemia

Juliette Schefelker, BA, Xiao Zhang, PhD, Ann Dodge, RN BSN APNP, Kristen Marten, DO, Greigory Dmailig, BS, Heather L. Bartlett, MD, Amy L. Peterson, MDMS\*

Department of Pediatrics, Division of Pediatric Cardiology, University of Wisconsin School of Medicine and Public Health, USA

## KEYWORDS

COVID-19;  
Lipid clinic;  
Cardiometabolic health;  
Health behavior;  
Lipid panel

**Background:** The COVID-19 pandemic has raised concerns for worsening cardiometabolic health in children.

**Objective:** This study evaluates the impact of the COVID-19 pandemic and subsequent social restrictions on pediatric cardiometabolic health factors.

**Methods:** Retrospective review of patients in a pediatric lipid clinic in the year prior to (3/18/2019-3/17/2020) and during (3/18/2020-3/17/2021) the COVID-19 pandemic was performed. Physical findings (body mass index [BMI], waist circumference [WC], and blood pressure), laboratory markers of cardiometabolic health (lipid panel, insulin resistance, and liver transaminases), self-reported exercise time, and lipid-lowering medications (metformin, statin, omega-3 fatty acids, fenofibrate) were compared.

**Results:** 297 subjects met inclusion criteria. Among subjects prescribed no medications or on stable medication doses (n=241), there were few changes in lipid panels. Among subjects with new or increased medication doses between pre-pandemic and pandemic intervals (n=62), there were increases in triglycerides (p=0.019) and HgbA1c (p=0.046). There was no change in z-scores for both BMI and WC for either group.

**Conclusion:** We observed concerning trends in markers of cardiovascular disease health (dyslipidemia, insulin resistance, and diabetes), independent of changes in weight, in at-risk children during the recent COVID pandemic. Our findings suggest that this vulnerable population may benefit from more frequent monitoring and intense management during such events.

© 2022 National Lipid Association. Published by Elsevier Inc. All rights reserved.

---

*Abbreviations* : ALT, Alanine aminotransferase; ASCVD, Atherosclerotic cardiovascular disease; ASCVDRF, Atherosclerotic cardiovascular disease risk factor; BMI, Body Mass Index; BP, Blood pressure; DBP, Diastolic blood pressure; HDL-C, High-density lipoprotein cholesterol; HgbA1c, Hemoglobin A1c; LDL-C, Low-density lipoprotein cholesterol; LLM, Lipid Lowering Medication; Non-HDL-C, Non-high-density

---

lipoprotein cholesterol; SBP, Systolic blood pressure; TC, Total cholesterol; TG, Triglycerides; WC, Waist Circumference.

\* Corresponding author at: Pediatric Cardiology, University of Wisconsin-Madison School of Medicine and Public Health, H6/516B CSC MC 4180, 600 Highland Ave, Madison, WI, 53792, USA.

E-mail address: [apeterson@pediatrics.wisc.edu](mailto:apeterson@pediatrics.wisc.edu) (A.L. Peterson).

Submitted November 10, 2021. Received in revised form June 2, 2022. Accepted for publication June 13, 2022.

## Introduction

Cardiovascular disease secondary to atherosclerosis begins in youth and tracks over a lifetime<sup>1-5</sup>. Atherosclerotic cardiovascular disease (ASCVD) risk factors (RFs), such as dyslipidemia, elevated blood pressure (BP) and increased body mass index (BMI) in children correlate with increased ASCVD risk in adulthood<sup>4-8</sup>. Metabolic risk factors including increased insulin resistance and type 2 diabetes have also been associated with increased ASCVD risk<sup>9-12</sup>.

Early treatment of ASCVDRFs has been shown to reduce risk of ASCVD events, such as stroke and myocardial infarction, in adulthood<sup>6,9</sup>. Thus, early prevention, identification, and treatment of ASCVDRFs in children is essential to promote cardiometabolic health<sup>7,9,10</sup>. Most treatments for ASCVDRFs in children are centered around lifestyle changes that encourage a diet with fruits and vegetables, limited sugared beverages and processed carbohydrates, regular physical activity, and maintenance of a healthy BMI<sup>9,10,13</sup>.

Since the onset of the COVID-19 pandemic, subsequent social restrictions and school closures have subjected children to significant stressors, including restrictions from attending school and participation in regular physical activities, as well as changes in dietary patterns<sup>14-16</sup>. During the COVID-19 pandemic, many have observed an increase in lifestyle habits associated with risk of premature ASCVD, such as decreased physical activity, increases in screen time (both for school and leisure), increased and altered eating habits, and deviations from normal sleep patterns<sup>14-16</sup>. These changes all have the potential to worsen cardiometabolic health. Recent data have demonstrated an increased incidence and severity for new-onset type 2 diabetes<sup>17-19</sup>, an increase in pediatric BMI<sup>20-22</sup>, and worsening exercise capacity<sup>22,23</sup> during the pandemic. Furthermore, decreased socioeconomic status from unemployment or underemployment of parents may exacerbate existing disparities including food insecurity and access to care<sup>24-26</sup>. However, formal analysis of the impact the COVID-19 pandemic on pediatric cardiometabolic health has been limited.

The aim of this study was to investigate the impact of the COVID-19 pandemic on cardiometabolic health markers of children seen at a pediatric lipid clinic. These markers included physical exam findings, laboratory studies, self-reported exercise time, and medication prescription rates. We hypothesized that children with risk factors for premature ASCVD had worsening markers of cardiometabolic health during the COVID-19 pandemic compared to markers obtained in the year prior to the pandemic.

## Methods

### Study population

The institutional pediatric lipid clinic database was queried for all clinical encounters during two time intervals:

1) the year prior to the COVID-19 pandemic (March 18, 2019 to March 17, 2020) and 2) the year during the COVID-19 pandemic (March 18, 2020- March 17, 2021). Early in the pandemic, there were marked differences in the impact on children based on geographic area. Therefore, for the purposes of our study, March 18, 2020 was chosen as the start of the pandemic as this was the date schools in our state were required to stop in-person instruction under a statewide executive order<sup>27</sup>. To qualify for inclusion, subjects needed at least one clinical encounter in both timeframes. Both in-person and virtual visits were included. Exclusion criteria included diagnosis of a genetic dyslipidemia syndrome or use of a medication which unpredictably alters the lipid panel (in this study, atypical antipsychotics, PEG-asparaginase, and isotretinoin). This study was deemed exempt by the institutional review board.


### Measures

The following measures were analyzed: (1) physical exam findings including BMI, waist circumference, systolic blood pressure (SBP) and diastolic blood pressure (DBP); (2) laboratory measures of cardiometabolic health: lipid panel (total cholesterol [TC], HDL-C, TG, LDL-C, non-HDL-C), markers of insulin resistance (fasting insulin, fasting glucose, and HgbA1c), and a marker of fatty liver disease (ALT); (3) self-reported hours of exercise; and (4) prescriptions of lipid-lowering medications (LLMs): statins, off-label metformin, fenofibrate, and omega-3 fatty acids. Although the effects of metformin on the lipid panel are indirect, it is commonly used to treat dyslipidemia due to insulin resistance in pediatrics, and so is included as a lipid-lowering medication here. Subjects were instructed to fast for at least 10 hours prior to collection of insulin, glucose, and lipid panels. Demographic information including sex and age were collected.

### Statistical analysis

As dosing changes to LLMs is a significant confounder to evaluation of lipids and insulin resistance, we divided the subjects into two groups: those with (1) either no LLM prescriptions or with stable LLM dosages across both timeframes, and (2) those with LLM prescriptions which increased between the pre-pandemic and during-pandemic periods, or who were newly prescribed a LLM in the pandemic interval.

BMI and WC data were converted to standardized z-scores<sup>28,29</sup>. Descriptive statistics were calculated, and average values for lab results, physical exam findings, and self-reported hours of exercise from each time period were compared between pre- and during-pandemic periods via paired t-tests. If a measurement was missing from a subject's paired data, then that subject was excluded from that particular analysis (i.e., if there was no WC measurement from during the pandemic, that subject was not used for a paired t-test for WC). Cohen's D was calculated to reflect effect size and a



**Fig. 1** illustrates the inclusion and exclusion criteria to select the final study sample.

corrected form was used to adjust for sample size to eliminate bias<sup>30</sup>. As suggested by Cohen,  $d = 0.2$  is considered a small effect size,  $d = 0.5$  medium, and  $d = 0.8$  large<sup>31</sup>. A value  $< 0.05$  was considered statistically significant. Analyses were performed with IBM SPSS Statistics for Windows, version 27 (IBM Corp., Armonk, NY).

## Results

### Subjects

Of the 608 subjects evaluated for inclusion in the lipid clinic between March 18, 2019 and March 17, 2021, 297 subjects met inclusion criteria (Fig. 1). Among excluded subjects, 299 were excluded because they did not have a visit during the pandemic, 62 were excluded because of a diagnosis of a primary genetic dyslipidemia syndrome (most commonly familial hypercholesterolemia), and 16 were excluded due to use of medications that unpredictably alter the lipid panel. Six subjects were excluded due to stopping or decreasing the dosage of an LLM.

A total of 245 subjects were either prescribed no LLM or had stable LLM dosages across both timeframes. In comparison, 52 subjects had increased LLM dosages or new LLM prescriptions in the pandemic timeframe (Table 1).

### Physical exam, laboratory measures, and exercise

Table 2 shows the comparison of lab results and physical exam findings between the pre-pandemic and during-pandemic periods. Of all subjects, 98.5% reported fasting prior to having laboratory tests performed.

Among the 245 subjects prescribed no LLM or with stable LLM dose, there were no changes in z-scores for both BMI and WC. Of this group, 14.3% were classified as diabetic (defined as HgbA1c  $> 6.5\%$  at any time during the study); one subject had new-onset diabetes during the pandemic (Supplemental Figure 1b). There was no change in self-reported hours of exercise.

Among the 52 subjects with increased LLM dosages or new LLM prescriptions between the pre-pandemic and pandemic intervals, there were also no changes in z-scores for both BMI and WC. These subjects had significant changes in laboratory results including increases in TC ( $201.9 \pm 38.95$  vs  $209.7 \pm 38.95$  mg/dL,  $p = 0.05$ ), non-HDL-C ( $157.7 \pm 35.59$  vs  $165.4 \pm 36.92$  mg/dL,  $p = 0.04$ ), TG ( $171.2 \pm 98.45$  mg/dL vs  $196.3 \pm 103.15$  mg/dL,  $p = 0.02$ ), HgbA1c ( $6.9\% \pm 2.23$  vs  $7.35\% \pm 2.60$ ,  $p = 0.02$ ), and ALT ( $36.60 \pm 38.92$  vs  $42.90 \pm 58.60$ ,  $p = 0.05$ ). There was also a trend towards increased fasting insulin (Table 2). Of these subjects, 39.1% were classified as diabetic; no subjects in this group were diagnosed with new-onset diabetes (Supplemental Figure 1b). There were no significant changes in LDL-C or HDL-C. There was a statistically significant decrease in hours of exercise ( $0.94 \pm 0.94$  hours vs.  $0.58 \pm 0.45$  hours,  $p = 0.05$ ).

## Discussion

Pediatric patients in a subspecialty lipid clinic demonstrated no significant changes in z-scores for both BMI and WC in the year of the COVID-19 pandemic compared to the year prior. Among subjects with no changes in LLM, changes in the lipid panel were statistically, but not clinically, significant. However, there was subset of subjects who did have statistically and clinically significant changes in their lipid panel (including increased TC, non-HDL-C, and TG). In these sub-

**Table 1** Baseline Demographics of Study Population

Measure	No LLM or Stable LLM (n=245)	New or increased LLM (n=52)	Total (n=297)
Age, mean (SD)	14.5 (3.0)	16.3 (3.4)	14.9 (3.12)
Female sex, n (%)	119 (48.6%)	26 (50%)	145 (48.8%)
Race, n (%)			
White	140 (57.1%)	34 (65.4%)	174 (58.6%)
Black/ African American	13 (5.3%)	2 (3.8%)	15 (5.1%)
Asian	7 (2.9%)	1 (1.9%)	8 (2.7%)
American Indian or Alaska Native	4 (1.6%)	0 (0%)	4 (1.3%)
Unavailable	81 (33.0%)	15 (28.8%)	96 (32.3%)

**Table 2** Physical Exam, Laboratory, and Self-Reported Hours of Exercise Results

	No LLM or Stable LLM (n=245)					New LLM or Increased LLM (n=52)				
	Pre-Pandemic, Mean (SD)	During Pandemic, Mean (SD)	n	Cohen's d	P	Pre-Pandemic, Mean (SD)	During Pandemic, Mean (SD)	n	Cohen's d (Hedge's correction)	P
<b>Physical Exam</b>										
BMI z-score	1.54 (1.10)	1.53 (1.12)	88	0.37	0.73	1.33 (1.18)	1.31 (1.24)	18	0.09	0.70
Waist circumference z-score	1.30 (1.05)	1.37 (1.10)	75	0.14	.23	0.99 (1.31)	1.15 (1.15)	15	0.416	0.11
Systolic blood pressure (mmHg)	63.8 (29.70)	69.2 (25.48)	27	0.16	0.43	79.6 (10.08)	86.2 (15.97)	5	0.43	0.3
Diastolic blood pressure (mmHg)	52.4 (18.49)	60.9 (18.60)	27	0.38	0.06	61.5 (18.09)	71.0 (28.94)	5	0.23	0.56
<b>Laboratory Markers</b>										
TC (mg/dL)	188.7 (36.21)	184.6 (38.41)	213	0.16	0.024	201.9 (38.95)	209.7 (38.95)	50	0.28	0.05
HDL-C (mg/dL)	45.1 (13.07)	45.3 (14.09)	215	0.03	0.66	43.7 (11.20)	44.3 (10.99)	50	0.09	0.53
LDL-C (mg/dL)	114.6 (31.05)	109.0 (30.79)	210	0.24	< 0.001	126.0 (35.96)	129.2 (33.77)	49	0.13	0.34
Non-HDL-C (mg/dL)	143.28 (31.33)	139.2 (34.13)	213	0.17	0.016	157.7 (35.59)	165.4 (36.93)	50	0.29	0.04
Triglycerides (mg/dL)	153.4 (117.54)	158.10 (111.93)	214	0.07	0.34	171.2 (98.45)	196.3 (103.15)	50	0.35	0.02
Insulin (uIU/mL)	35.02 (21.35)	37.75 (20.19)	78	0.14	0.23	28.35 (14.78)	36.06 (16.67)	12	0.56	0.06
HgbA1c (%)	5.7 (1.18)	5.7 (1.12)	84	0.02	0.85	6.9 (2.23)	7.35 (2.60)	23	0.49	0.02
Glucose (mg/dL)	93.55 (14.80)	92.91 (22.58)	99	0.05	0.60	98.14 (27.28)	108.02 (58.14)	21	0.28	0.19
ALT (U/L)	42.60 (41.21)	41.21 (34.66)	99	0.05	0.60	36.70 (38.92)	42.90 (58.60)	30	0.37	0.05
<b>Exercise</b>										
Hours of Exercise	0.84 (0.64)	0.85 (1.04)	127	-0.07	0.14	0.94 (0.94)	0.58 (0.45)	29	0.37	0.05

ALT= Alanine aminotransferase; BMI= body mass index; HDL-C= high-density lipoprotein cholesterol; HgbA1c=hemoglobin A1c; LDL-C= low-density lipoprotein cholesterol; LLM= lipid-lowering medication; Non-HDL-C= non- high-density lipoprotein cholesterol; TG = triglycerides.

jects, increases in HgbA1c, fasting insulin, TC, TG, and ALT were indicative of worsening insulin resistance, dyslipidemia, and hepatic steatosis, respectively. These markers, particularly those indicating worsening insulin resistance (increased fasting insulin and HgbA1c), are consistent with reports of higher rates of pediatric type 2 diabetes during the pandemic<sup>17-19</sup>.

Notably, there was no increase in z-scores for both BMI and WC in the year of the COVID pandemic compared to the year prior in either group. As these scores are standardized and control for age and gender, in the group with no changes in LLM this may be a further indicator of minimal changes during this period. However, in the group of subjects with changes in LLM who demonstrated worsening insulin resistance and increasing TGs (as described above), we speculate

that the lack of change may indicate an increase in adiposity with corresponding decrease in lean muscle mass, or maintenance of a stable caloric intake with deterioration in diet quality. This is particularly noteworthy, as a clinician may be tempted to focus their monitoring efforts towards children and adolescents who have had significant increases in their BMI over the pandemic period. Our data would suggest that these children, who are already at high cardiometabolic risk, worsened their cardiometabolic parameters without significantly increasing their BMI. An approach that focuses solely on children with significant BMI increase may miss many children with worsening cardiometabolic health.

This study shows a decrease in hours of exercise only in subjects requiring a new or increased dose in LLM, suggesting that this change may have contributed to the worsening



of laboratory measures seen in this group. This is consistent with other reports of decreased physical activity in children during the pandemic<sup>14–16</sup>.

There were 299 subjects who failed to seek care in the year of the pandemic. We speculate that some of these subjects may represent lower-risk or well-controlled patients, for whom missing a follow-up would not be detrimental to their care. In this light, our study population, subjects who sought care during the pandemic, may represent a higher-risk subgroup than initially thought. However, it is equally possible that some of these subjects may be at higher risk, as financial hardships, lack of access or desire to participate in a telemedicine encounter, parental illness or increased parental responsibilities could all be reasons for missing follow-up.

Limitations to this study include its observational and retrospective nature; while other studies have also reported unhealthy lifestyle changes in association with the pandemic, we cannot establish causality. Our study may have limited generalizability as this is a report from a single center. Furthermore, our study population included children previously diagnosed with dyslipidemia, and therefore had already been identified as a population at high risk for ASCVD. In our study, the population that continued to seek care during the pandemic year had higher TG and HgbA1c compared to the subjects that were excluded (Supplemental Table 1). Our study included both in-person and virtual visits. We were unable to collect all physical exam data during virtual visits, which decreased sample number for those results and may have made them less robust than desired. In addition, our measure of exercise was self-reported, which is a less reliable measure of physical activity.

Interestingly, our data suggest that there is a subset of children (i.e., the group with new or increased LLMs) who are particularly vulnerable from a cardiometabolic standpoint, as they experienced significant changes in laboratory markers, whereas most children in our study did not have significant changes in their laboratory markers. Future research to better characterize which children are particularly at risk for abrupt worsening of laboratory markers would help identify these children who could benefit from more frequent monitoring or earlier pharmacotherapy. Furthermore, future studies to investigate long-term impact of these changes via longitudinal follow-up would help to determine if the changes demonstrated in this study resolve or persist over time. Finally, previous studies suggested that social restrictions due to the pandemic had a greater impact on already vulnerable populations, such as families with lower socioeconomic status or children with pre-existing health conditions<sup>20,26</sup>. Our data set did not include measures of socioeconomic status, making this a potential area for future investigation.

## Conclusion

Our study shows concerning trends in markers of ASCVD health (dyslipidemia, insulin resistance, and diabetes), inde-

pendent of changes in weight, in at-risk children during the COVID-19 pandemic. The findings suggest that this vulnerable population may benefit from more frequent monitoring and intense management during such events.

## Contributor's statement

Ms. Scheffelker collected data, carried out initial analyses, drafted the initial manuscript, and reviewed and revised the manuscript.

Dr. Zhang designed data collection instruments, coordinated and supervised data collection, and reviewed and revised the manuscript.

Ms. Dodge conceptualized and designed the study, reviewed and revised the manuscript.

Dr. Marten designed the data collection instruments, and reviewed and revised the manuscript.

Mr. Dimailig contributed to data interpretation and reviewed and revised the manuscript.

Dr. Bartlett contributed to data interpretation and reviewed and revised the manuscript.

Dr. Peterson conceptualized and designed the study, coordinated and supervised data collection, and reviewed and revised the manuscript.

All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

## Declaration of Competing Interest

Ms. Dodge owns stock in Pfizer, Medtronic, Johnson and Johnson, and Merck. Ms. Scheffelker, Dr. Zhang, Dr. Marten, Mr. Demailig, Dr. Bartlett, and Dr. Peterson declare no conflicts of interest.

## Funding/Support

We acknowledge the support for a summer research award from the [Herman and Gwendolyn Shapiro Foundation](#).

## Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:[10.1016/j.jacl.2022.06.006](https://doi.org/10.1016/j.jacl.2022.06.006).

## References

1. Enos W, Holmes R, Beyer J. Coronary disease among United States soldiers killed in action in Korea; preliminary report. *J Am Med Assoc*. 1953;152(12):1090–1093. doi:[10.1001/jama.1953.03690120006002](https://doi.org/10.1001/jama.1953.03690120006002).
2. Newman 3rd W, Freedman D, Voors A, et al. Relation of serum lipoprotein levels and systolic blood pressure to early atherosclerosis. The Bogalusa Heart Study. *N Engl J Med*. 1986;314(3):138–144. doi:[10.1056/NEJM198601163140302](https://doi.org/10.1056/NEJM198601163140302).

3. McGill HCJ, McMahan CA, Malcom GT, Oalmann MC, Strong JP. Effects of serum lipoproteins and smoking on atherosclerosis in young men and women. The PDAY Research Group. Pathobiological Determinants of Atherosclerosis in Youth. *Arterioscler Thromb Vasc Biol.* 1997;17(1):95–106. doi:10.1161/01.atv.17.1.95.
4. McGill HCJ, McMahan CA. Determinants of atherosclerosis in the young. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. *Am J Cardiol.* 1998;82(10B):30T–36T. doi:10.1016/s0002-9149(98)00720-6.
5. Berenson GS, Srinivasan SR, Bao W, Newman W, Tracy RE, Wattigney W. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. *N Engl J Med.* 1998;338(23):1605–1606. doi:10.1056/NEJM199806043382302.
6. Zhang Y, Vittinghoff E, Pletcher MJ. Associations of blood pressure and cholesterol levels during young adulthood with later cardiovascular events. *J Am Coll Cardiol.* 2019;74(3):330–341. doi:10.1016/j.jacc.2019.03.529.
7. Patel SS, Daniels SR. Beginning With the End in Mind: the Case for Primordial and Primary Cardiovascular Prevention in Youth. *Can J Cardiol.* 2020;36:1344–1351.
8. McCrindle BW. Cardiovascular Consequences of Childhood Obesity. *Can J Cardiol.* 2015;31(2):124–130. doi:10.1016/j.cjca.2014.08.017.
9. Baker Smith C, Peterson A. Preventing Premature Atherosclerotic Disease. *Curr Hypertens Rep.* 2020;22(87).
10. Lazarte J, Hegele R. Pediatric Dyslipidemia– Beyond Familial Hypercholesterolemia. *Can J Cardiol* 36:1362–1372.
11. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and Management of the Metabolic Syndrome. *Circulation.* 2005;112(17):2735–2752. doi:10.1161/CIRCULATIONAHA.105.169404.
12. Steinberger J, Daniels SR. Insulin Resistance, Diabetes, and Cardiovascular Risk in Children: An American Heart Association Scientific Statement From the Atherosclerosis, Hypertension, and Obesity in the Young Committee (Council on Cardiovascular Disease in the Young) and the Diabetes Committee (Council on Nutrition, Physical Activity, and Metabolism). *Circulation.* 2003;107(10):1448–1453. doi:10.1161/01.CIR.0000060923.07573.F2.
13. Steinberger J, Daniels SR, Hagberg N, et al. Cardiovascular Health Promotion in Children: Challenges and Opportunities for 2020 and Beyond: A Scientific Statement From the American Heart Association. *Circulation.* 2016;134(12):e236–e255. doi:10.1161/CIR.0000000000000441.
14. Dunton GF, Do B, Wang SD. Early effects of the COVID-19 pandemic on physical activity and sedentary behavior in children living in the U.S. *BMC Public Health.* 2020;20(1):1351. doi:10.1186/s12889-020-09429-3.
15. Pietrobelli A, Pecoraro L, Ferruzzi A, et al. Effects of COVID-19 Lockdown on Lifestyle Behaviors in Children with Obesity Living in Verona, Italy: A Longitudinal Study. *Obesity.* 2020;28(8):1382–1385.
16. Moore SA, Faulkner G, Rhodes RE, et al. Impact of the COVID-19 virus outbreak on movement and play behaviours of Canadian children and youth: a national survey. *Int J Behav Nutr Phys Act.* 2020;17(1):85. doi:10.1186/s12966-020-00987-8.
17. Hsia DS, Lim M, Beyl RA, Hasan HA, Gardner J. 153-LB: Initial Presentation of Children with Type 2 Diabetes during the COVID-19 Pandemic. *Diabetes.* 2021;70(Supplement 1):153 -LB. doi:10.2337/db21-153-LB.
18. Marks BE, Khilnani A, Meyers A, et al. 15-OR: The COVID-19 Pandemic and New-Onset Pediatric Type 2 Diabetes. *Diabetes.* 2021;70(Supplement 1):15 -OR. doi:10.2337/db21-15-OR.
19. Riaz A, Gordner C, Ehresman A. 182-LB: Hospitalizations for Hyperglycemic Crisis during COVID-19 Pandemic. *Diabetes.* 2021;70(Supplement 1):182 -LB. doi:10.2337/db21-182-LB.
20. Brooks CG, Spencer JR, Sprafka JM, et al. Pediatric BMI changes during COVID-19 pandemic: An electronic health record-based retrospective cohort study. *EclinicalMedicine.* 2021;38:101026. doi:10.1016/j.eclinm.2021.101026.
21. Woolford SJ, Sidell M, Li X, et al. Changes in Body Mass Index Among Children and Adolescents During the COVID-19 Pandemic. *JAMA.* 2021 Published online August 27. doi:10.1001/jama.2021.15036.
22. Jarnig G, Jaunig J, van Poppel MNM. Association of COVID-19 Mitigation Measures With Changes in Cardiorespiratory Fitness and Body Mass Index Among Children Aged 7 to 10 Years in Austria. *JAMA Netw Open.* 2021;4(8):e2121675 -e2121675. doi:10.1001/jamanetworkopen.2021.21675.
23. Dayton JD, Ford K, Carroll SJ, Flynn PA, Kourtidou S, Holzer RJ. The Deconditioning Effect of the COVID-19 Pandemic on Unaffected Healthy Children. *Pediatr Cardiol.* 2021;42(3):554–559. doi:10.1007/s00246-020-02513-w.
24. DiMeglio LA, Albanese O'Neill A, Munoz CE, Maahs DM. COVID-19 and Children with Diabetes– Updates, Unknowns, and Next Steps: First, Do No Extrapolation. *Diabetes Care.* 2020;43:2631–2634.
25. Addala A, Auzanneau M, Miller K, et al. A decade of disparities in diabetes technology use and HbA1c in pediatric type 1 diabetes: a transatlantic comparison. *Diabetes Care.* 2021;44(1):133–140. doi:10.2337/dc20-0257.
26. Wanberg CR, Csillag B, Douglass RP, Zhou L, Pollard MS. Socioeconomic status and well-being during COVID-19: A resource-based examination. *J Appl Psychol.* 2020;105(12):1382–1392. doi:10.1037/apl0000831.
27. Palm A. *Order for Statewide School Closure.* 2020. Published online March 13 Accessed September 17, 2021. <https://dpi.wi.gov/sites/default/files/imce/administrators/e-mail/03-13-2020.pdf>.
28. Kuczmarski RJ, Ogden CL, Guo SS, et al. 2000 CDC Growth Charts for the United States: methods and development. *Vital Health Stat 11.* 2002(246):1–190.
29. Sharma AK, Metzger DL, Daymont C, Hadjiyannakis S, Rodd CJ. LMS tables for waist-circumference and waist-height ratio Z-scores in children aged 5–19 y in NHANES III: association with cardio-metabolic risks. *Pediatr Res.* 2015;78(6):723–729. doi:10.1038/pr.2015.160.
30. Hedges L. Distribution theory for Glass's estimator of effect size and related estimators. *J Educ Stat.* 1981;6:107–128.
31. Cohen J. A power primer. *Psychol Bull.* 1992;112(1):155–159. doi:10.1037//0033-2909.112.1.155.